Repligen climbs as investors lean into 2026 guidance and bioprocessing rebound
Repligen shares rose about 3.8% as investors focused on the company’s recently issued 2026 outlook and margin-expansion plan ahead of its next earnings update. The last company update guided 2026 revenue to $810 million–$840 million with adjusted EPS of $1.93–$2.01, keeping the bioprocessing-recovery narrative in play.
1. What’s moving the stock
Repligen (RGEN) traded higher today, extending a recent rebound as the market continues to re-rate bioprocessing names into the next earnings window. The most recent company-provided fundamental catalyst remains its February 24, 2026 quarterly report and outlook, where management issued full-year 2026 guidance that framed a growth-and-margins improvement story for the year.
2. The key numbers investors are anchoring to
In its latest results release, Repligen provided 2026 revenue guidance of $810 million to $840 million and guided to adjusted EPS of $1.93 to $2.01, alongside a plan that implies operating leverage as demand normalizes. That outlook has stayed central to the bull case—bioprocessing recovery plus execution-driven margin expansion—particularly after the stock’s pullback from earlier highs.
3. What to watch next
The next major catalyst is the upcoming Q1 2026 earnings report (widely tracked for updates to full-year guidance, order trends, and bioprocessing demand visibility). Traders will also monitor incremental analyst actions and any management commentary on demand normalization across end markets and regions, since even small changes to growth or margin assumptions can drive outsized moves at current valuation levels.